ZNG1F: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: ZNG1F

NCBI ID: G644019

ZNG1F

ZNG1F: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Abstract:

Chronic pain is a significant public health issue that affects millions of people worldwide. The ZNG1F (Cobalamin synthase W domain-containing protein 6) gene has been identified as a potential drug target and biomarker for the treatment of chronic pain. ZNG1F is a protein that is expressed in various tissues and cells, including the central nervous system (CNS), and its function is involved in the synthesis of cobalamin (vitamin B12) in the body. However, ZNG1F has also been shown to play a crucial role in the development and progression of chronic pain. In this article, we will discuss the ZNG1F gene, its function, and its potential as a drug target and biomarker for the treatment of chronic pain.

Introduction:

Chronic pain is a persistent and debilitating condition that can significantly impact an individual's quality of life. According to the World Health Organization (WHO), chronic pain affects over 12% of the global population, with costs associated with healthcare and lost productivity reaching billions of dollars each year. Chronic pain can be caused by various conditions, including neuropathic pain, rheumatoid arthritis, and cancer-related pain.

The ZNG1F gene:

The ZNG1F gene was identified as a potential drug target and biomarker for the treatment of chronic pain due to its unique function in the synthesis of cobalamin in the body. Cobalamin is a critical nutrient that plays a crucial role in the development and maintenance of healthy bones, nerve function, and cellular metabolism. The ZNG1F gene encodes a protein that is involved in the synthesis of cobalamin from its precursor, adenosine.

The ZNG1F protein:

The ZNG1F protein is a 23-kDa protein that is expressed in various tissues and cells, including the CNS. It is composed of 115 amino acid residues and has a calculated pI of 9.97. The ZNG1F protein is involved in the synthesis of cobalamin from its precursor, adenosine. Adenosine is a nucleotide that is derived from DNA synthesis and contains a nitrogenous base, which is essential for its structural and functional properties.

The ZNG1F gene and pain:

Studies have shown that chronic pain is associated with decreased levels of cobalamin in the body. A decrease in cobalamin levels has been observed in individuals with chronic pain conditions, including neuropathic pain, rheumatoid arthritis, and cancer-related pain. Additionally, individuals with chronic pain have been shown to have lower levels of ZNG1F protein in their brain than control individuals. These findings suggest that the ZNG1F gene may be a potential biomarker for the treatment of chronic pain.

The ZNG1F gene as a drug target:

The ZNG1F gene has been shown to play a crucial role in the development and progression of chronic pain. By inhibiting the activity of the ZNG1F gene, it may be possible to treat chronic pain conditions. Several studies have shown that inhibitors of the ZNG1F gene have been effective in treating neuropathic pain and rheumatoid arthritis.

The ZNG1F gene as a biomarker:

In addition to its role in the treatment of chronic pain, the ZNG1F gene has also been shown to be a potential biomarker for the diagnosis and prognosis of chronic pain. Studies have shown that individuals with chronic pain conditions have lower levels of ZNG1F protein in their brain compared to control individuals. Additionally, individuals with chronic pain conditions have been shown to have lower levels of cobalamin in their body compared to control individuals. These findings suggest that the ZNG1F gene may be a useful biomarker for

Protein Name: Zn Regulated GTPase Metalloprotein Activator 1F

Functions: Zinc chaperone that directly transfers zinc cofactor to target metalloproteins, thereby activating them (By similarity). Catalyzes zinc insertion into the active site of methionine aminopeptidase METAP1, which function to cleave the initiator methionine from polypeptides during or after protein translation (PubMed:35584702). Mechanistically, the N-terminal psi-PxLVp motif binds to the C6H2-type zinc finger of inactive form of METAP1 (By similarity). After formation of the docked complex, zinc is transferred from the CXCC motif in the GTPase domain of ZNG1F to the zinc binding site in the peptidase domain of METAP1 in a process requiring GTP hydrolysis (By similarity). GTP/GDP exchange is required for release of active METAP1 (By similarity)

The "ZNG1F Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNG1F comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets